Converting to Insulin Degludec/Liraglutide (IDegLira) Is Efficacious Regardless of Pretrial Insulin Dose in Patients with Type 2 Diabetes (T2D) Uncontrolled on Insulin Glargine U100 (IGlar)

被引：0
|
作者：
Meneghini, Luigi F.
Jaeckel, Elmar
Leiter, Lawrence A.
Lingvay, Ildiko
Harvey, John N.
Begtrup, Kamilla
Chandarana, Keval
Vilsboll, Tina
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1093-P
引用
收藏
页码：A289 / A289
页数：1
相关论文
共 50 条
  • [1] Converting to IDegLira is efficacious regardless of pre-trial insulin dose in patients with type 2 diabetes uncontrolled on insulin glargine U100
    Meneghini, L. F.
    Jaeckel, E.
    Leiter, L. A.
    Lingvay, I.
    Harvey, J. N.
    Begtrup, K.
    Chandarana, K.
    Vilsboll, T.
    DIABETOLOGIA, 2017, 60 : S306 - S306
  • [2] Efficacy and Safety of Insulin Degludec (IDeg) vs. Insulin Glargine U100 (IGlar) in Hispanic Patients with Type 2 Diabetes (T2D)
    Chaykin, Louis B.
    Bhargava, Anuj
    Wysham, Carol H.
    Abrahamsen, Trine
    Van Leeuwen, Michiel
    De la Rosa, Raymond
    DIABETES, 2017, 66 : A617 - A617
  • [3] Safe and Effective Lowering of Blood Glucose with Insulin Degludec/Liraglutide (IDegLira) in Elderly Patients with Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs and/or Insulin Glargine (IGlar)
    Lingvay, Ildiko
    Sorli, Christopher H.
    Linjawi, Sultan
    Abrahamsen, Trine J.
    Lehmann, Lucine
    Liebl, Andreas
    DIABETES, 2016, 65 : A265 - A265
  • [4] Insulin Degludec Has Lower Hypoglycemia Risk than Insulin Glargine U100 in Older People with Type 2 Diabetes (T2D)
    Heller, Simon R.
    Devries, J. Hans
    Wysham, Carol H.
    Hansen, Charlotte T.
    Hansen, Melissa V.
    Frier, Brian M.
    DIABETES, 2018, 67
  • [5] An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
    Evans, Marc
    Billings, Liana K.
    Hakan-Bloch, Jonas
    Slothuus, Ulla
    Abrahamsen, Trine J.
    Andersen, Andreas
    Jansen, Jeroen P.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (04) : 340 - 347
  • [6] A reduced risk of hypoglycaemia with insulin degludec vs. insulin glargine U100 in Asian insulin-naive patients with T2D
    Yang, Wenying
    Li, Qiang
    Li, Zhengfang
    Yang, Jin-Kui
    Ye, Shandong
    Hansen, Charlotte
    Xu, Hongfei
    Pan, Changyu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S115 - S115
  • [7] Effect of insulin degludec U100 vs insulin glargine U100 on time in range in patients with type 2 diabetes at risk of hypoglycaemia
    Goldenberg, R.
    Aroda, V. R.
    Billings, L. K.
    Christiansen, A. S. L.
    Donatsky, A. M.
    Rizi, E. Parvaresh
    Podgorski, G.
    Raslova, K.
    Klonoff, D. C.
    Bergenstal, R. M.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S318 - S319
  • [8] Higher derived time in range with insulin degludec/insulin aspart vs insulin glargine U100 in Japanese adults with T2D
    Philis-Tsimikas, A.
    D'Cruz, J. M.
    De Block, C.
    Hachmann-Nielsen, E.
    Sivarathinasami, R.
    Onishi, Y.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [9] Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
    Gough, Stephen C. L.
    Jain, Rajeev
    Woo, Vincent C.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (01) : 7 - 19
  • [10] Higher Derived Time-in-Range with IDegLira vs. Insulin Glargine U100 in Patients with T2D
    Philis-Tsimikas, Athena
    Aroda, Vanita R.
    De Block, Christophe
    Billings, Liana K.
    Hachmann-Nielsen, Elise
    Liebl, Andreas
    Sivarathinasami, Ramsathish
    D'Cruz, John M.
    Lingvay, Ildiko
    DIABETES, 2021, 70
12345